In the present study, we have characterized signalling cross-talk between STAT5b (signal transducer and activator of transcription 5b) and HNF4α (hepatocyte nuclear factor 4α), two major regulators of sex-dependent gene expression in the liver. In a HepG2 liver cell model, HNF4α strongly inhibited β-casein and ntcp (Na + /taurocholate cotransporting polypeptide) promoter activity stimulated by GH (growth hormone)-activated STAT5b, but had no effect on interferon-γ -stimulated STAT1 transcriptional activity. By contrast, STAT5b synergistically enhanced the transcriptional activity of HNF4α towards the ApoCIII (apolipoprotein CIII) promoter. The inhibitory effect of HNF4α on STAT5b transcription was associated with the inhibition of GH-stimulated STAT5b tyrosine phosphorylation and nuclear translocation. The short-chain fatty acid, butyrate, reversed STAT5b transcriptional inhibition by HNF4α, but did not reverse the inhibition of STAT5b tyrosine phosphorylation. HNF4α inhibition of STAT5b tyrosine phosphorylation was not reversed by pervanadate or by dominant-negative phosphotyrosine phosphatase 1B, suggesting that it does not result from an increase in STAT5b dephosphorylation. Rather, HNF4α blocked GHstimulated tyrosine phosphorylation of JAK2 (Janus kinase 2), a STAT5b tyrosine kinase. Thus STAT5b and HNF4α exhibit bidirectional cross-talk that may augment HNF4α-dependent gene transcription while inhibiting STAT5b transcriptional activity via the inhibitory effects of HNF4α on JAK2 phosphorylation, which leads to inhibition of STAT5b signalling initiated by the GH receptor at the cell surface.
INTRODUCTION
HNF4α (hepatocyte nuclear factor 4α) is a liver-enriched member of the nuclear receptor superfamily that regulates the expression of genes involved in fatty acid, cholesterol and glucose metabolism, apolipoprotein synthesis and liver development [1] [2] [3] . HNF4α regulates the expression of genes in liver, both directly and indirectly, through interaction with other HNFs, including the variant homeodomain protein HNF1α, C/EBPs (CCAAT/enhancerbinding proteins), HNF3 winged helix factors and the one-cut homeoprotein, HNF6 [4] . These HNFs are, in turn, regulated through a complex transcriptional-control hierarchy that determines the relative expression and activity of other HNF family members. Among the HNFs, HNF4α is proposed to play a central role in the regulation of liver-enriched transcription factors and their liver-specific targets, including liver CYP (cytochrome P450) genes [5] . The key regulatory role of HNF4α was demonstrated in a liver-HNF4α-deficient mouse model [2] , in which HNF4α was shown to control the expression of HNFs in vivo in both a positive manner (HNF1α, C/EBPα and C/EBPβ) and a negative manner {HNF3α, HNF3β, HNF6 and the HNF4α coactivator, PGC-1α [PPARγ (peroxisome-proliferator-activated receptor γ ) co-activator-1 α]} [6] .
HNF4α is also a key regulator of many hepatic CYP genes, as demonstrated by in vitro promoter analyses [7] [8] [9] [10] , by expression of HNF4α antisense transcripts [11] and by characterization of mice with a liver-specific deficiency of HNF4α [2, 6] . In particular, HNF4α was shown to determine the expression of a unique subset of mouse liver genes which differs markedly between the sexes. Notably, HNF4α was shown to positively regulate several malespecific genes whereas it negatively regulates certain femalepredominant genes through a mechanism that is operative in male, but not female, mouse liver [6, 12] .
The transcription of sex-dependent liver CYP genes is regulated by GH (growth hormone), which is secreted into the bloodstream in a sex-dependent manner. The resultant plasma GH profiles, pulsatile in males and more continuous in females, regulate the sexually dimorphic expression of liver CYPs through a mechanism that is proposed to involve the GH-activated transcription factor, STAT5b (signal transducer and activator of transcription 5b) [13] . GH signalling is initiated by the binding of GH to its plasma membrane receptor, which induces activation/tyrosine phosphorylation of the GH-receptor-associated tyrosine kinase, JAK2 (Janus kinase 2). JAK2, in turn, phosphorylates a tyrosine residue on the GH receptor, followed by tyrosine phosphorylation and nuclear translocation of STAT5b [14] . This pathway for STAT5b activation is uniquely responsive to the male (pulsatile) plasma GH pattern; it results in a high level of active STAT5b in adult male, but not female, rat liver, coincident with each plasma GH pulse [15] [16] [17] . GH induces a similar sex-dependent activation of STAT5b in mouse liver [18] . The importance of this pathway is evident from the characterization of STAT5b-deficient male mice [19, 20] , which exhibit impaired body growth from approx. 4 weeks of age and a global loss of sex-dependent liver CYP expression [21] .
In vivo studies, as well as in vitro promoter analyses of liver CYP genes, indicate that STAT5b may require collaborative interaction with other factors, in particular HNFs, to achieve the strong male CYP transcriptional responses observed in vivo [5] . Signalling cross-talk between STAT5b and HNF3β has been reported, whereby STAT5b inhibits HNF3β-dependent trans-activation of a male-specific CYP promoter, while HNF3β blocks STAT5b transactivation by inhibiting GH-stimulated STAT5b tyrosine phosphorylation [22] . Co-operative interaction between STAT5b and HNF4α leading to regulation of a female-specific CYP promoter has also been described [23] . Finally, both stimulatory and inhibitory cross-talk may occur between STAT5b and certain nuclear receptors [24] [25] [26] .
In the present study, we have used a liver cell model to investigate signalling cross-talk between STAT5b and HNF4α. We demonstrate that STAT5b enhances HNF4α-dependent transactivation of the ApoCIII (apolipoprotein CIII) promoter. By contrast, HNF4α is shown to inhibit GH-and STAT5b-stimulated β-casein and ntcp (Na + /taurocholate cotransporting polypeptide) promoter activity by blocking JAK2 tyrosine phosphorylation, which leads to inhibition of STAT5b tyrosine phosphorylation and nuclear translocation. Together, these findings suggest that metabolic and other factors associated with elevated HNF4α activity in liver may suppress STAT5b activation and transcriptional activity, and that hormonal factors associated with a high level of STAT5b activity may lead to an increase in HNF4α-dependent gene transcription.
MATERIALS AND METHODS

Antibodies
A rabbit polyclonal anti-STAT5b antibody (sc-835), raised against STAT5b residues 776-786, was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). A rabbit polyclonal antipTyr 699 -STAT5b (where pTyr is phosphorylated tyrosine) antibody, raised against a synthetic phosphotyrosine peptide (keyhole-limpet-haemocyanin-coupled) surrounding Tyr 699 of mouse STAT5b, was purchased from Cell Signaling Technology (Beverly, MA, U.S.A.). Recombinant proteins containing a V5 epitope were detected using a mouse monoclonal anti-V5 antibody (Invitrogen, Carlsbad, CA, U.S.A.). A rabbit anti-HNF4α antibody raised against a synthetic peptide corresponding to amino acids 445-455 of rat HNF4α1 was obtained from Dr F. Sladek (Department of Pharmacology, University of California, Riverside, CA, U.S.A.). Rabbit polyclonal antibodies against JAK2 and pTyr 1007/1008 -JAK2 were purchased from Upstate Biotech (Lake Placid, NY, U.S.A.).
Expression and reporter plasmids
An expression plasmid encoding rat HNF4α, corresponding to the α1 splice variant, was obtained from Dr F. Sladek and was used in all experiments, except where human HNF4α was used, as has been noted. Human HNF4α cloned into pCDNA3 was obtained from 
Western blotting
Cell lysates used for Western blotting were centrifuged for 30 min at 15 000 g, and samples (20 µg/well) were electrophoresed on 7.5 % Laemmli SDS gels, electrotransferred on to a nitrocellulose membrane and then probed with an antibody against STAT5b or pTyr 699 -STAT5b, as described in the manufacturer's protocol. Antibody binding was visualized on X-ray film by enhanced chemiluminescence using the ECL ® kit from Amersham Biosciences. Nitrocellulose membranes were heated in stripping buffer [62.5 mM Tris/HCl (pH 7.6), 2 % SDS and 50 mM 2-mercaptoethanol] for 20 min at 50
• C and then probed with a rabbit polyclonal anti-HNF4α or mouse monoclonal anti-V5 antibody. Membranes were blocked in Solution I (0.3 % Tween-20 in 1 × PBS) containing 1 % BSA and 1 % non-fat dried milk for 1 h at 37
• C and then incubated overnight with an anti-HNF4α antibody (1:2000 dilution in blocking solution) at 4
• C. Membranes probed with other antibodies were blocked for 1 h at 37
• C in blocking solution containing 5 % non-fat dried milk, then incubated overnight at 4
• C with anti-V5 (1:5000), anti-JAK2 (1:1000) or anti-pTyr 1007/1008 -JAK2 (1:1000) antibodies diluted in blocking solution.
Immunofluorescence studies
Growth and passage of CWSV-1 cells was carried out as described [28] . Confocal immunofluorescence analysis of STAT5b and pTyr 699 -STAT5b, and the visualization of GH-stimulated STAT5b nuclear translocation were carried out as described [29] , with the following modifications. Methanol-fixed cells were blocked with 3 % charcoal-stripped BSA in PBS for 1 h at room temperature then incubated overnight at 4
• C in blocking solution containing an anti-STAT5b antibody (1:500 dilution). For anti-pTyr 699 -STAT5b immunostaining, methanol-fixed cells were blocked with 5.5 % charcoal-stripped BSA in TBST [50 mM Tris/HCl (pH 7.4), 150 mM NaCl and 0.1 % Triton X-100] for 1 h at room temperature and then incubated for 24 h in a humidified environment at 4
• C with the anti-pTyr 699 -STAT5b antibody (1:500 dilution) in TBS [50 mM Tris/HCl (pH 7.4) and 150 mM NaCl] containing 3 % BSA. The samples were then washed three times with PBS containing 3 % BSA (for anti-STAT5b antibody) or with TBST (for anti-pTyr 699 -STAT5b antibody) (5 min/wash). For V5 immunostaining, fixed cells were blocked for 30 min at room temperature with 1 % BSA in PBS (blocking buffer) and incubated with an anti-V5 antibody (diluted in 1:200 in blocking buffer) either for 1 h at room temperature or overnight at 4
• C. Cells were then incubated for 1 h at 37
• C with an FITCconjugated goat anti-(rabbit IgG) antibody(1 µg/ml; Molecular Probes, Eugene, OR, U.S.A.). Cells were counterstained with 10 ng/ml propidium iodide (Sigma) to localize nuclei.
RESULTS
HNF4α inhibition of STAT5b tyrosine phosphorylation
HNF4α is required for the expression of certain sex-specific GHregulated liver CYP genes, several of which also require STAT5b [6, 12] . We therefore investigated the possibility of signalling cross-talk between these two liver-expressed transcription factors. GH-stimulated STAT5b signalling was reconstituted in HepG2 cells by transfection with the GH receptor and STAT5b, together with the STAT5 reporter plasmid 4x-ntcp-Luc, which contains four copies of a STAT5-response element derived from the GHresponsive rat ntcp gene. Co-transfection of HNF4α resulted in a dose-dependent inhibition of GH-stimulated reporter activity ( Figure 1A, left) . The inhibitory effect of HNF4α was verified using a second STAT5 reporter, pZZ1-Luc, which contains a 345 nt fragment of the prolactin-responsive β-casein gene and includes a pair of STAT5 sites in their natural promoter context ( Figure 1B) . The specificity of the HNF4α inhibitory response was apparent from the absence of STAT5b inhibition in cells transfected with HNF1α in place of HNF4α ( Figure 1A , right) and from the fact that HNF4α did not inhibit STAT1 transcriptional activity in cells stimulated with interferon-γ ( Figure 1C ). More potent inhibition of STAT5b transcriptional activity was observed using a different expression plasmid, which codes for human HNF4α ( Figure 1D ) and gave a several fold higher level of HNF4α protein expression in the transfected cell lysates compared with the rat HNF4α expression plasmid used in Figure 1 (A) (results not shown).
Western blot analysis was carried out to ascertain whether HNF4α affects STAT5b tyrosine phosphorylation, which is stimulated by GH treatment and is required for STAT5b transcriptional activity. Figure 1 (E) demonstrates that HNF4α inhibited the GH-stimulated phosphorylation of STAT5b on Tyr 699 , as indicated by the substantial decrease in pTyr 699 -STAT5b immunoreactivity (lane 6 versus lane 4) and by the decrease in the ratio of tyrosine phosphorylated STAT5b to unphosphorylated STAT5b, detected with an anti-STAT5b antibody. This inhibitory effect on STAT5b tyrosine phosphorylation was dose-dependent, as shown using human HNF4α ( Figure 1E , lanes 10 and 12 versus lane 8).
Stimulatory effect of STAT5b on the HNF4α-dependent ApoCIII promoter
We next investigated whether the inhibitory effect of HNF4α on STAT5b transcription is mutual, as reported for STAT5b and another nuclear receptor, PPAR [30] . To examine the effect of STAT5b on HNF4α-dependent transcription, we used a reporter gene based on ApoCIII, a well-established HNF4α target gene. ApoCIII-Luc reporter activity was stimulated by HNF4α, both in HepG2 cells (an approx. 3-4-fold increase) and in COS-1 cells (an approx. 14-16-fold increase) (Figure 2A ). Although STAT5b alone had little or no effect on ApoCIII promoter activity, HNF4α-stimulated ApoCIII activity was increased approx. 4-fold further upon co-transfection with STAT5b in HepG2 cells and in COS-1 cells. STAT5b had no effect on the expression of HNF4α protein under the conditions of these experiments (results not shown). Moreover, in the case of HepG2 cells, ApoCIII promoter activity was further enhanced by GH treatment. The enhanced activity of HNF4α by STAT5b was markedly decreased when STAT5b was replaced with STAT5b-Y699F ( Figure 2B ), which is defective in DNA binding and transcriptional activity owing to mutation of the tyrosine phosphorylation site to phenylalanine.
Effect of a short-chain fatty acid on HNF4α inhibitory effects
Structural studies have revealed that fatty acids serve as endogenous ligands of HNF4α [31, 32] . Moreover, short-chain fatty acids, such as butyrate, can enhance GH-induced STAT5b activity [33] . We therefore investigated whether the inhibitory effect of HNF4α on STAT5b activation (Figure 1 ) is influenced by butyrate. Figure 3(A) shows that butyrate treatment of HepG2 cells induced a modest dose-dependent increase in STAT5b transcriptional activity. In cells expressing HNF4α, the magnitude of the stimulatory effect from butyrate was increased more substantially, such that the inhibitory effect of HNF4α on STAT5b-dependent transcription was abolished at 1000 µM butyrate. Western blot analysis showed, however, that butyrate did not reverse the inhibition of STAT5b tyrosine phosphorylation by HNF4α ( Figure 3B , lane 8 versus lane 6). Thus butyrate renders STAT5b hyperactive, by a mechanism that does not alter STAT5b tyrosine phosphorylation or reverse the inhibitory effect of HNF4α.
Impact of HNF4α on STAT5b nuclear translocation
GH-activated STAT5b translocates from the cytosol to the nucleus, where it binds to STAT5 response elements and transactivates GH-responsive target genes. We therefore investigated whether inhibition of STAT5b transcriptional activity by HNF4α is associated with the inhibition of STAT5b nuclear translocation. GH-stimulated STAT5b nuclear translocation was visualized in HepG2 cells by confocal immunofluorescence microscopy 
Effect of HNF4α on the time course of STAT5b phosphorylation and dephosphorylation
The inhibitory effect of HNF4α on STAT5b tyrosine phosphorylation could result from a decrease in the rate, and/or the maximal extent of STAT5b tyrosine phosphorylation. Alternatively, HNF4α could activate (or induce) tyrosine phosphatases that down-regulate GH signalling to STAT5b by catalysing dephosphorylation of the GH receptor, JAK2 or STAT5b itself. To address these questions, we first investigated the impact of HNF4α on the kinetics of STAT5b tyrosine phosphorylation in GHstimulated HepG2 cells. STAT5b tyrosine phosphoryation was To further investigate whether an increase in STAT5b tyrosine phosphatase activity may contribute to the HNF4α-dependent decrease in maximal pTyr-STAT5b signal, HepG2 cells were treated with GH in the presence of pervanadate, a general PTP inhibitor, in an effort to dampen down the inhibitory effect of HNF4α. Western blot analysis revealed, however, that STAT5b tyrosine phosphorylation was substantially inhibited by HNF4α, independently of the presence of pervanadate ( Figure 6A , lane 8 versus lane 4). We therefore investigated the effect of PTP-1B-D181A, a dominant-negative mutant of the STAT5b tyrosine phosphatase PTP-1B [34] . pTyr 699 -STAT5b is a good substrate for PTP-1B, which may contribute to the dephosphorylation and deactivation of STAT5b that occurs in hormone-stimulated cells. PTP-1B may also contribute to the down-regulation of GH receptor signalling by dephosphorylation of the GH receptor [35] and/or JAK2 [36] . We first confirmed that PTP-1B blocks GH-stimulated STAT5b transcriptional activity ( Figure 6B , bar 2 versus bar 1). Next, we demonstrated that PTP-1B-D181A reverses the inhibitory effect of PTP-1B in a dose-dependent manner (bars 3 and 4 versus bar 2). Finally, we examined the effect of PTP-1B-D181A on the HNF4α-dependent inhibition of STAT5b activity. No reversal of HNF4α inhibition was observed ( Figure 6B , bar 6 versus bar 5). A similar result was obtained using TC-PTP-C216S, a dominant-negative inhibitor of TC-PTP [37] , which also catalyses pTyr-STAT5b dephosphorylation (results not shown).
HNF4α inhibits JAK2 tyrosine phosphorylation
Given the role of tyrosine-phosphorylated JAK2 in catalysing GHinduced STAT5b tyrosine phosphorylation [14] , we investigated whether JAK2 tyrosine phosphorylation is altered by HNF4α. These experiments were carried out in HepG2 cells transfected with JAK2 in order to increase the sensitivity for detection of pTyr-JAK2. HNF4α effected a dose-dependent inhibition of JAK2 tyrosine phosphorylation, as revealed by Western blotting using an antibody against pTyr 1007/1008 -JAK2 ( Figure 7A ). This inhibition paralleled that of STAT5b tyrosine phosphorylation and was more HepG2 cells were transfected with the GH receptor and STAT5b, alone or in combination with a V5-HNF4α expression plasmid [STAT5b/HNF4α, 1:5 (w/w)]. Cells were stimulated with 200 ng/ml GH for the time period indicated. Cell extracts were then prepared and analysed on a Western blot probed sequentially for pTyr 699 -STAT5b, total STAT5b protein and V5-HNF4α. HNF4α inhibited the maximal level, but had no effect on the rate, of STAT5b tyrosine phosphorylation (A, lanes 6-10 versus lanes 1-5). The rate of STAT5b dephosphorylation was apparently increased somewhat in the presence of HNF4α (B, lanes 6-8 versus lanes 2-4). The time course for GH-induced STAT5b phosphorylation and dephosphorylation in HepG2 cells is slower than in CWSV-1 cells [46] . extensive than the non-specific decrease in the level of JAK2 protein seen at higher levels of HNF4α plasmid. The latter nonspecific decrease did not require the GH receptor ( Figure 7A , lanes 3 and 4 versus lanes 1 and 2) and was independent of GH treatment ( Figure 7A lanes 7, 9, 11 and 13 versus lanes 8,  10, 12 and 14) . The inhibition of JAK2 tyrosine phosphorylation was also observed using human HNF4α ( Figure 7B , lane 2 and lane 4 versus lane 6). We conclude that HNF4α inhibits JAK2 signalling to STAT5b in a manner that decreases STAT5b tyrosine phosphorylation, nuclear translocation and transcriptional activity.
DISCUSSION
In the present study we have characterized bi-directional crosstalk between STAT5b and HNF4α, which both play important roles in liver gene expression, in particular sex-dependent, GHregulated gene expression, as revealed by the analysis of knockout mouse models [6, 12, 21] . We also demonstrate that STAT5b enhances HNF4α-dependent gene transcription, while HNF4α is shown to inhibit GH-stimulated STAT5b tyrosine phosphorylation, nuclear translocation and transcriptional activity. Consequently, the relative functional expression levels of HNF4α and STAT5b may be an important determinant of the activity of both transcription factors, with conditions that are associated with a high level of HNF4α activity inhibiting STAT5b activation and STAT5b transcriptional activity, and conditions associated with high STAT5b activity augmenting HNF4α, as well as STAT5b transcriptional activity. STAT5b is repeatedly activated, and then deactivated, approx. every 3.5-4 h in direct response to each plasma GH pulse in the adult male rat [16, 17] , raising the possibility that STAT5b-and HNF4α-stimulated transcriptional events may both be influenced by the pulsatile, male plasma-GH rhythm. This latter possibility is consistent with the sex-dependent effects that HNF4α has on certain GH-dependent hepatic genes [6, 12] . In the present study, HNF4α has been shown to inhibit STAT5b transcriptional activity by blocking STAT5b tyrosine phosphorylation that is catalysed by the GH-receptor-associated tyrosine kinase JAK2. This inhibition was observed when using both rat and human HNF4α. The inhibitory effect of HNF4α was manifested at the level of GH-stimulated JAK2 phosphorylation of Tyr 1007/1008 , which is causally linked to the activation of JAK2 catalytic activity [38] . By contrast, HNF4α did not inhibit interferon-γ -stimulated STAT1 transcriptional activity, which is mediated by the interferon-γ receptor and requires both JAK1 and JAK2 [39, 40] . Further evidence for the specificity of the HNF4α inhibitory response includes our finding that STAT5b activation was not inhibited by HNF1α. In previous studies, we found that HNF3β, a forkhead transcription factor unrelated to HNF4α, can also inhibit STAT5b tyrosine phosphorylation [22] , however, the mechanism for that inhibition has not been determined.
The mechanism by which HNF4α inhibits JAK2 phosphorylation is unknown. Given the major role of HNF4α in regulating liver gene expression [2, 6, 41] , HNF4α may act by inducing the expression of one or more factors that block JAK2 activation or stimulate JAK2 deactivation (dephosphorylation) in GH-stimulated cells. For example, HNF4α may induce the expression of one or more JAK2-inhibitory cytokine receptor signalling inhibitors, such as SOCS (suppressor of cytokine signalling) 1 and SOCS3 [42] . Although SOCS induction is classically stimulated in liver cells by GH and other cytokine receptor ligands, another nuclear receptor family member, oestrogen receptor-α, can mediate oestradiol-stimulated SOCS induction [43] . Alternatively, HNF4α may induce, or activate, tyrosine phosphatases, such as PTP-1B [36] or SHP-2 (Src homology 2 domain-containing PTP) [44] . The latter possibility is suggested by the increase in the apparent rate of STAT5b tyrosine dephosphorylation observed in the presence of HNF4α. However, HNF4α inhibition was not reversed by pervanadate, a general tyrosine phosphatase inhibitor, or by the expression of dominant-negative inhibitors of PTP-1B and TC-PTP, which catalyse dephosphorylation of activated GH receptor [35] , JAK2 [36] and STAT5b [34, 45] . It is probable that the apparent increase in the rate of STAT5b dephosphorylation reflects the upstream inhibition of JAK2-catalysed STAT5b tyrosine phosphorylation, which has the effect of rapidly decreasing the steady-state pool of pTyr-STAT5b [46] . Finally, HNF4α inhibition of JAK2 phosphorylation could also involve 'non-genomic' (i.e. non-transcriptional), membraneassociated signalling events analogous to those described for other members of the nuclear receptor superfamily [47] .
Cross-talk between STAT5b and several other nuclear receptors has been reported. Bi-directional inhibitory cross-talk between STAT5 and oestrogen receptor-α [48, 49] , thyroid hormone receptor [24, 50] and PPARα and PPARγ have been described [25, 30, 51] . In contrast with the present findings using HNF4α, however, the inhibition of STAT5 transcriptional activity by PPARs occurs at a step downstream from the JAK2-catalysed tyrosine phosphorylation step [25] . In the case of oestrogen receptor-α, direct interaction with STAT5, requiring the oestrogen receptor-α DNA-binding domain, has been reported [49] . Finally, in direct contrast with our findings using HNF4α, cross-talk between STAT5 and the glucocorticoid receptor that is synergistic towards STAT5 transcription but is inhibitory towards glucocorticoid receptor-dependent transcription has been described [26] .
HNF4α is widely regarded as a constitutively active (i.e. ligandindependent) nuclear receptor. Structural studies have revealed the presence of a previously unrecognized fatty acid docked in the ligand-binding domain of HNF4α [31, 32] , consistent with the finding that fatty acids regulate HNF4α-dependent gene expression [52, 53] . Fatty acids may also modulate STAT5 activity [54, 55] . We therefore investigated whether fatty acids could modulate the inhibitory cross-talk between HNF4α and STAT5b. Indeed, we found that the short-chain fatty acid, butyrate, stimulated STAT5b transcriptional activity to a greater extent in cells expressing HNF4α than in its absence, effectively reversing the inhibition of STAT5b transcriptional activity. However, butyrate did not reverse HNF4α inhibition of STAT5b tyrosine phosphorylation, indicating that it acts by a distinct mechanism, and suggesting that STAT5b transcriptional activity is hyperactive in its presence.
ApoCIII is an HNF4α target gene, as demonstrated by in vitro promoter analyses [56, 57] and verified by the decreased expression of ApoCIII in a liver HNF4α-deficient mouse model [2, 6] and in human patients with mutations in HNF4α [58] . In the present study, HNF4α activated the human ApoCIII promoter in HepG2 hepatoma cells, and to an even greater extent in COS-1 cells, which are devoid of the low level of endogenous HNF4α found in HepG2 cells. STAT5b enhanced the trans-activation of ApoCIII by HNF4α in a manner that was apparently synergistic and analogous to that observed previously using two male-specific CYP genes [27] . The ApoCIII promoter fragment used in these studies (nt − 852 to + 22) contains a consensus HNF4α-binding site, nt − 465 to − 457, but does not include a binding site matching the classic STAT5 consensus sequence, TTC-NNN-GAA. Although STAT5b binding to non-consensus sites may occur [59] , it is possible that the stimulatory effects of STAT5b on HNF4α-activated ApoCIII described here occur in the absence of direct STAT5b-DNA binding. This possibility is supported by the partial stimulation of ApoCIII promoter activity by the DNAbinding-deficient STAT5b-Y699F ( Figure 2B ). Further studies are required to establish the mechanism for this stimulatory effect of STAT5b and its overall importance in the regulation of HNF4α-dependent gene expression in liver. The possibility that STAT5b may play an important role in HNF4α-directed gene expression is supported by the co-dependence of several CYPs and other GHregulated, sex-specific genes on HNF4α and STAT5b that have been recently described in mouse liver [12] .
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